Depletion of B220⁺NK1.1⁺ cells enhances the rejection of established melanoma by tumor-specific CD4⁺ T cells

References

• Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics 2011; 29(10):863-74; PMID:21846158; http://dx.doi.org/10.2165/11589300-000000000-00000
   PubMed Web of Science ®Google Scholar
• Gardere S, Hussain S, Cowan DH. Treatment of metastatic malignant melanoma with a combination of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388), cyclophosphamide (NSC-26271), and vincristine (NSC-67574). Cancer Chemother Rep 1972; 56(3):357-61; PMID:19051495
   PubMedGoogle Scholar
• Foletto MC, Haas SE. Cutaneous melanoma: new advances in treatment. Anais Bras De Dermatol 2014; 89(2):301-10; PMID:24770508; http://dx.doi.org/10.1590/abd1806-4841.20142540
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17(7):2105-16; PMID:10561265
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11(2):155-64; PMID:20004617; http://dx.doi.org/10.1016/S1470-2045(09)70334-1
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384(9948):1109-17; PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2
   PubMed Web of Science ®Google Scholar
• Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013; 31(34):4311-18; PMID:24145345; http://dx.doi.org/10.1200/JCO.2013.51.4802
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8):711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, Fulton A, Tamada K, Strome SE, Antony PA. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 2013; 190(9):4899-909; PMID:23536636; http://dx.doi.org/10.4049/jimmunol.1300271
   PubMed Web of Science ®Google Scholar
• Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207(3):637-50; PMID:20156971; http://dx.doi.org/10.1084/jem.20091918
   PubMed Web of Science ®Google Scholar
• Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207(3):651-67; PMID:20156973; http://dx.doi.org/10.1084/jem.20091921
   PubMed Web of Science ®Google Scholar
• Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174(5):2591-601; PMID:15728465; http://dx.doi.org/10.4049/jimmunol.174.5.2591
   PubMed Web of Science ®Google Scholar
• Overwijk WW,Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003; 198(4):569-80; PMID:12925674; http://dx.doi.org/10.1084/jem.20030590
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12(4):269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191
   PubMed Web of Science ®Google Scholar
• June C, Rosenberg SA, Sadelain M, Weber JS. T-cell therapy at the threshold. Nat Biotechnol 2012; 30(7):611-14; PMID:22781680; http://dx.doi.org/10.1038/nbt.2305
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6(5):383-93; PMID:16622476; http://dx.doi.org/10.1038/nri1842
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298(5594):850-54; PMID:12242449; http://dx.doi.org/10.1126/science.1076514
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002; 25(3):243-51; PMID:12000866; http://dx.doi.org/10.1097/00002371-200205000-00007
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202(7):907-12; PMID:16203864; http://dx.doi.org/10.1084/jem.20050732
   PubMed Web of Science ®Google Scholar
• Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007; 117(8):2197-204; PMID:17657310; http://dx.doi.org/10.1172/JCI32205
   PubMed Web of Science ®Google Scholar
• Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 2007; 13(18 Pt 1):5280-9; PMID:17875756; http://dx.doi.org/10.1158/1078-0432.CCR-07-1378
   PubMed Web of Science ®Google Scholar
• Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010; 33(1):1-7; PMID:19952961; http://dx.doi.org/10.1097/CJI.0b013e3181b88ffc
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26(32):5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449
   PubMed Web of Science ®Google Scholar
• Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109(12):5346-54; PMID:17327412; http://dx.doi.org/10.1182/blood-2006-10-051318
   PubMed Web of Science ®Google Scholar
• Ohteki T, Suzue K, Maki C, Ota T, Koyasu S. Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response. Nat Immunol 2001; 2(12):1138-43; PMID:11702064; http://dx.doi.org/10.1038/ni729
   PubMed Web of Science ®Google Scholar
• Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12(2):214-9; PMID:16444265; http://dx.doi.org/10.1038/nm1356
   PubMed Web of Science ®Google Scholar
• Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier LL et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006; 12(2):207-13; PMID:16444266; http://dx.doi.org/10.1038/nm1352
   PubMed Web of Science ®Google Scholar
• Guimont-Desrochers F, Lesage S. Revisiting the prominent anti-tumoral potential of pre-mNK cells. Front Immunol 2013; 4:446; PMID:24376447; http://dx.doi.org/10.3389/fimmu.2013.00446
   PubMed Web of Science ®Google Scholar
• Guimont-Desrochers F, Boucher G, Dong Z, Dupuis M, Veillette A, Lesage S. Redefining interferon-producing killer dendritic cells as a novel intermediate in NK-cell differentiation. Blood 2012; 119(19):4349-57; PMID:22353997; http://dx.doi.org/10.1182/blood-2011-11-395954
   PubMed Web of Science ®Google Scholar
• Huarte E, Rynda-Apple A, Riccardi C, Skyberg JA, Golden S, Rollins MF, Ramstead AG, Jackiw LO, Maddaloni M, Pascual DW. Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE. J Autoimmun 2011; 37(4):328-41; PMID:22018711; http://dx.doi.org/10.1016/j.jaut.2011.09.005
   PubMed Web of Science ®Google Scholar
• Perona-Wright G, Mohrs K, Szaba FM, Kummer LW, Madan R, Karp CL, Johnson LL, Smiley ST, Mohrs M. Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe 2009; 6(6):503-12; PMID:20006839; http://dx.doi.org/10.1016/j.chom.2009.11.003
   PubMed Web of Science ®Google Scholar
• Maroof A, Beattie L, Zubairi S, Svensson M, Stager S, Kaye PM. Posttranscriptional regulation of II10 gene expression allows natural killer cells to express immunoregulatory function. Immunity 2008; 29(2):295-305; PMID:18701085; http://dx.doi.org/10.1016/j.immuni.2008.06.012
   PubMed Web of Science ®Google Scholar
• Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006; 12(11):1301-9; PMID:17041596; http://dx.doi.org/10.1038/nm1492
   PubMed Web of Science ®Google Scholar
• Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H, et al. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res 2012; 72(11):2757-67; PMID:22427351; http://dx.doi.org/10.1158/0008-5472.CAN-11-3379
   PubMed Web of Science ®Google Scholar
• Cook KD, Whitmire JK. The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection. J Immunol 2013; 190(2):641-9; PMID:23241878; http://dx.doi.org/10.4049/jimmunol.1202448
   PubMed Web of Science ®Google Scholar
• Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cell-mediated graft-versus-host disease. J Immunol 2010; 184(12):6790-8; PMID:20488796; http://dx.doi.org/10.4049/jimmunol.0902598
   PubMed Web of Science ®Google Scholar
• Goding SR, Wilson KA, Antony PA. Combination of adoptive cell transfer, anti-PD-L1 and anti-LAG-3 antibodies for the treatment of recurrent tumors: better with more. Oncoimmunology 2013; 2(8):e25050; http://dx.doi.org/10.4161/onci.25050
   Web of Science ®Google Scholar
• Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11(5):330-42; PMID:21508983; http://dx.doi.org/10.1038/nri2970
   PubMed Web of Science ®Google Scholar
• Schuster IS, Wikstrom ME, Brizard G, Coudert JD, Estcourt MJ, Manzur M, O'Reilly LA, Smyth MJ, Trapani JA, Hill GR et al. TRAIL+ NK cells control CD4+ T cell responses during chronic viral infection to limit autoimmunity. Immunity 2014; 41(4):646-56; PMID:25367576; http://dx.doi.org/10.1016/j.immuni.2014.09.013
   PubMed Web of Science ®Google Scholar
• Lu L, Ikizawa K, Hu D, Werneck MB, Wucherpfennig KW, Cantor H. Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity 2007; 26(5):593-604; PMID:17509909; http://dx.doi.org/10.1016/j.immuni.2007.03.017
   PubMed Web of Science ®Google Scholar
• Young WW Jr, Hakomori SI, Durdik JM, Henney CS. Identification of ganglio-N-tetraosylceramide as a new cell surface marker for murine natural killer (NK) cells. J Immunol 1980; 124(1):199-201; PMID: 6985637; http://dx.doi.org/10.1016/j.immuni.2007.03.017
   PubMed Web of Science ®Google Scholar
• Bakema JE, van Egmond M. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Curr Topics Microbiol Immunol 2014; 382:373-92; PMID:25116109
   PubMed Web of Science ®Google Scholar
• Chen XL, Bobbala D, Cepero Donates Y, Mayhue M, Ilangumaran S, Ramanathan S. IL-15 trans-presentation regulates homeostasis of CD4(+) T lymphocytes. Cell Mol Immunol 2014; 11(4):387-97; PMID:24658435; http://dx.doi.org/10.1038/cmi.2014.13
   PubMed Web of Science ®Google Scholar
• Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 2002; 195(12):1523-32; PMID:12070280; http://dx.doi.org/10.1084/jem.20020066
   PubMed Web of Science ®Google Scholar
• Purton JF, Tan JT, Rubinstein MP, Kim DM, Sprent J, Surh CD. Antiviral CD4+ memory T cells are IL-15 dependent. J Exp Med 2007; 204(4):951-61; PMID:17420265; http://dx.doi.org/10.1084/jem.20061805
   PubMed Web of Science ®Google Scholar
• Blasius AL, Barchet W, Cella M, Colonna M. Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J Exp Med 2007; 204(11):2561-8; PMID:17923504; http://dx.doi.org/10.1084/jem.20070991
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005; 26(2):111-7; PMID:15668127; http://dx.doi.org/10.1016/j.it.2004.12.003
   PubMed Web of Science ®Google Scholar
• Jiang Q, Wei H, Tian Z. IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma. J Immunother 2008; 31(6):555-62; PMID:18528299; http://dx.doi.org/10.1097/CJI.0b013e31817d8e75
   PubMed Web of Science ®Google Scholar
• Himoudi N, Nabarro S, Buddle J, Eddaoudi A, Thrasher AJ, Anderson J. Bone marrow-derived IFN-producing killer dendritic cells account for the tumoricidal activity of unpulsed dendritic cells. J Immunol 2008; 181(9):6654-63; PMID:18941256; http://dx.doi.org/10.4049/jimmunol.181.9.6654
   PubMed Web of Science ®Google Scholar
• Himoudi N, Yan M, Bouma G, Morgenstern D, Wallace R, Seddon B, Buddle J, Eddaoudi A, Howe SJ, Cooper N et al. Migratory and antigen presentation functions of IFN-producing killer dendritic cells. Cancer Res 2009; 69(16):6598-606; PMID:19654308; http://dx.doi.org/10.1158/0008-5472.CAN-09-0501
   PubMed Web of Science ®Google Scholar
• Saxena RK, Saxena QB, Adler WH. Defective T-cell response in beige mutant mice. Nature 1982; 295(5846):240-1; PMID:6977094; http://dx.doi.org/10.1038/295240a0
   PubMed Web of Science ®Google Scholar
• Terme M, Mignot G, Ullrich E, Bonmort M, Minard-Colin V, Jacquet A, Schultze JL, Kroemer G, Leclerc C, Chaput N et al. The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells. Cancer Res 2009; 69(16):6590-7; PMID:19679551; http://dx.doi.org/10.1158/0008-5472.CAN-08-4473
   PubMed Web of Science ®Google Scholar
• Pletneva M, Fan H, Park JJ, Radojcic V, Jie C, Yu Y, Chan C, Redwood A, Pardoll D, Housseau F. IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity. Cancer Res 2009; 69(16):6607-14; PMID:19679552; http://dx.doi.org/10.1158/0008-5472.CAN-09-0508
   PubMed Web of Science ®Google Scholar
• Boyman O, Purton JF, Surh CD, Sprent J. Cytokines and T-cell homeostasis. Curr Opin Immunol 2007; 19(3):320-26; PMID:17433869; http://dx.doi.org/10.1016/j.coi.2007.04.015
   PubMed Web of Science ®Google Scholar
• van Leeuwen EM, Sprent J, Surh CD. Generation and maintenance of memory CD4(+) T Cells. Curr Opin Immunol 2009; 21(2):167-72; PMID:19282163; http://dx.doi.org/10.1016/j.coi.2009.02.005
   PubMed Web of Science ®Google Scholar
• Boyman O, Krieg C, Homann D, Sprent J. Homeostatic maintenance of T cells and natural killer cells. Cell Mol Life Sci 2012; 69(10):1597-608; PMID:22460580; http://dx.doi.org/10.1007/s00018-012-0968-7
   PubMed Web of Science ®Google Scholar
• Osborne LC, Abraham N. Regulation of memory T cells by gammac cytokines. Cytokine 2010; 50(2):105-13; PMID:19879771; http://dx.doi.org/10.1016/j.cyto.2009.09.008
   PubMed Web of Science ®Google Scholar
• Van Belle T, Grooten J. IL-15 and IL-15Ralpha in CD4+T cell immunity. Arch Immunol Ther Exp 2005; 53(2):115-26; PMID:15928580; http://dx.doi.org/10.1007/s00018-012-0968-7
   PubMed Web of Science ®Google Scholar
• Van Belle TL, Dooms H, Boonefaes T, Wei XQ, Leclercq G, Grooten J. IL-15 augments TCR-induced CD4+ T cell expansion in vitro by inhibiting the suppressive function of CD25 High CD4+ T cells. PloS One 2012; 7(9):e45299; PMID: 23028916; http://dx.doi.org/10.1016/j.cyto.2009.09.008
   Google Scholar
• Goldszmid RS, Dzutsev A, Trinchieri G. Host immune response to infection and cancer: unexpected commonalities. Cell Host Microbe 2014; 15(3):295-305; PMID:24629336; http://dx.doi.org/10.1016/j.chom.2014.02.003
   PubMed Web of Science ®Google Scholar
• Miura Y, Misawa N, Maeda N, Inagaki Y, Tanaka Y, Ito M, Kayagaki N, Yamamoto N, Yagita H, Mizusawa H et al. Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J Exp Med 2001; 193(5):651-60; PMID:11238596; http://dx.doi.org/10.1084/jem.193.5.651
   PubMed Web of Science ®Google Scholar
• Hardy AW, Graham DR, Shearer GM, Herbeuval JP. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proc Natl Acad Sci U S A 2007; 104(44):17453-8; PMID:17956986; http://dx.doi.org/10.1073/pnas.0707244104
   PubMed Web of Science ®Google Scholar
• Guimont-Desrochers F, Cappello ZJ, Chagnon M, McDuffie M, Lesage S. Cutting edge: genetic characterization of IFN-producing killer dendritic cells. J Immunol 2009; 182(9):5193-7; PMID:19380763; http://dx.doi.org/10.4049/jimmunol.0803969
   PubMed Web of Science ®Google Scholar
• Toomer KH, Chen Z. Autoimmunity as a double agent in tumor killing and cancer promotion. Front Immunol 2014; 5:116; PMID:24672527; http://dx.doi.org/10.3389/fimmu.2014.00116
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4(127):127ra137; PMID:22461641;http://dx.doi.org/10.1126/scitranslmed.3003689
   Web of Science ®Google Scholar